Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
9
Job creation lowest on record among under-30s
-
10
Opposition chief acquitted of instigating perjury
Celltrion, a local bio company, on Monday had its biosimilar for an antibody against arthritis approved.
This is the first time an antibody copy treatment was approved in the world, the company said.
The Korea Food and Drug Administration on Monday authorized “Remsima,” a biosimilar of Janssen’s “Remicade.” The company has conducted clinical trials on a total of 856 patients from 29 countries.
The drug maker said Remsima could replace Remicade for use for rheumatic arthritis, ankylosing spondylitis, psoriasis and other conditions.
This is the first time an antibody copy treatment was approved in the world, the company said.
The Korea Food and Drug Administration on Monday authorized “Remsima,” a biosimilar of Janssen’s “Remicade.” The company has conducted clinical trials on a total of 856 patients from 29 countries.
The drug maker said Remsima could replace Remicade for use for rheumatic arthritis, ankylosing spondylitis, psoriasis and other conditions.
-
Articles by Korea Herald
